Alembic Pharmaceuticals Ltd
APLLTDAlembic Pharmaceuticals Ltd
APLLTDPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
37.19 | 4.86 | 0.92% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.91 | 6.64 | 0.47% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 3,173.11 | 3,107.17 | 3,137.84 | 3,944.06 | 4,610.69 | 5,480.42 | 5,361.53 | 5,655.36 | 6,256.93 | 6,323.27 | ||||||||||
Raw Materials | 877.07 | 928.05 | 927.62 | 1,084.97 | 1,249.98 | 1,451.27 | 1,489.61 | 1,630.17 | 1,857.92 | 5,333.65 | ||||||||||
Power & Fuel Cost | 58.89 | 64.20 | 70.35 | 88.86 | 102.40 | 118.72 | 120.84 | 151.54 | 173.37 | |||||||||||
Employee Cost | 472.85 | 558.83 | 622.81 | 746.69 | 906.44 | 1,051.17 | 1,133.00 | 1,169.13 | 1,446.29 | |||||||||||
Selling & Administrative Expenses | 507.40 | 791.13 | 700.51 | 961.11 | 913.65 | 1,104.03 | 1,354.87 | 1,474.00 | 1,543.70 | |||||||||||
Operating & Other expenses | 243.09 | 147.67 | 166.42 | 179.47 | 253.92 | 187.65 | 333.31 | 550.33 | 274.96 | |||||||||||
EBITDA | 1,013.81 | 617.29 | 650.13 | 882.96 | 1,184.30 | 1,567.58 | 929.90 | 680.19 | 960.69 | 989.62 | ||||||||||
Depreciation/Amortization | 72.21 | 82.97 | 105.46 | 115.23 | 157.32 | 183.48 | 286.78 | 275.43 | 272.67 | 275.53 | ||||||||||
PBIT | 941.60 | 534.32 | 544.67 | 767.73 | 1,026.98 | 1,384.10 | 643.12 | 404.76 | 688.02 | 714.09 | ||||||||||
Interest & Other Items | 5.43 | 5.23 | 3.40 | 18.41 | 27.16 | 16.02 | 17.73 | 50.17 | 56.19 | 54.98 | ||||||||||
PBT | 936.17 | 529.09 | 541.27 | 749.32 | 999.82 | 1,368.08 | 625.39 | 354.59 | 631.83 | 659.11 | ||||||||||
Taxes & Other Items | 216.12 | 125.93 | 128.64 | 164.95 | 171.00 | 221.58 | 104.45 | 12.60 | 16.01 | 29.18 | ||||||||||
Net Income | 720.05 | 403.16 | 412.63 | 584.37 | 828.82 | 1,146.50 | 520.94 | 341.99 | 615.82 | 629.93 | ||||||||||
EPS | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 59.55 | 26.50 | 17.40 | 31.33 | 32.05 | ||||||||||
DPS | 3.50 | 4.00 | 4.00 | 5.50 | 10.00 | 14.00 | 10.00 | 8.00 | 11.00 | 8.00 | ||||||||||
Payout ratio | 0.09 | 0.19 | 0.18 | 0.18 | 0.23 | 0.24 | 0.38 | 0.46 | 0.35 | 0.25 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Alembic Pharmaceuticals Ltd | 38.05 | 4.86 | 0.92% |
Sun Pharmaceutical Industries Ltd | 48.19 | 6.88 | 0.70% |
Cipla Ltd | 32.68 | 5.02 | 0.78% |
Torrent Pharmaceuticals Ltd | 68.98 | 16.66 | 0.83% |
Price Comparison
Compare APLLTD with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
DSP Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6435% | Percentage of the fund’s portfolio invested in the stock 5.14% | Change in the portfolio weight of the stock over the last 3 months 0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/33 (+1) |
Aditya Birla Sun Life Pharma & Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1086% | Percentage of the fund’s portfolio invested in the stock 2.95% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/30 (+3) |
Edelweiss Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0862% | Percentage of the fund’s portfolio invested in the stock 0.86% | Change in the portfolio weight of the stock over the last 3 months 0.86% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/81 (+14) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
APLLTD has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.92%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.23 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Dividend/Share
₹11.00
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateAug 17, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 17, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Dividend/Share
₹14.00
Ex DateEx Date
Jul 19, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹3.00
Ex DateEx Date
Mar 16, 2020
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lastacaft Solution of AbbVie Inc. Alcaftadine Ophthalmic Solution is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of pharmaceutical products, i.e. formulations and active pharmaceutical ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip fell 1.03% to currently trade at Rs 1229.35 on the BSE. Powered by Capital Market - Live
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lamictal XR Extended-Release Tablets, 200 mg, 250 mg, and 300 mg, of GlaxoSmithKline LLC (GSK). Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. Also indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg have an estimated market size of US$ 163 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 216 ANDA approvals (188 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live
Stocks t watch: Alembic Pharmaceuticals' oral solid formulation facility (F-1) located in Panelav, Gujarat received establishment inspection report (EIR) from United States Food and Drug Administration (USFDA), which was inspected by USFDA from 17 July to 26 July 2024. Bajel Projects had successfully entered the emerging data centre segment by securing its first order from an upcoming data centre service provider. The order involves the design and construction of a 220/33kV gas-insulated switchgear (GIS) substation and transmission line extension for a colocation data centre in Navi Mumbai, Maharashtra. Zydus Lifesciences received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg. Lupin's Pithampur facility in Madhya Pradesh, which includes the unit-1 API and finished product manufacturing site, has completed the U.S. Food and Drug Administration (USFDA) inspection with 3 observations. Adani Enterprises' unit April Moon will acquire a 74% stake in Cococart Ventures for Rs 200 crore. Adani Energy Solutions has signed a business transfer agreement with its subsidiary, North Maharashtra Power to carve out the Adani Dahanu Thermal Power Station. Adani Electricity Mumbai is a subsidiary of the company. IndusInd Bank's board has approved the re-apppointment of Sumant Kathpali as managing director & chief executive officer (CEO) for a term of three years, effective from 24 March 2025.This re-appointment is subject to approval by the reserve bank of India and bank's shareholder. Biocon's API facility (Site 2) in Bengaluru was inspected by US Food and Drug Administration (USFDA), from 23 September to 27 September 2024 ended with four observations.Powered by Capital Market - Live
Earlier, on 26 July 2024, the pharmaceutical company informed that it had successfully completed the USFDA inspection of its Oral Solid Formulation Facility (F-I) in Panelav. This scheduled GMP inspection was completed without any form 483 observations. The inspection had been conducted from 17 July 2024 to 26 July 2024. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. Shares of Alembic Pharma shed 0.27% to settle at Rs 1,192.65 on Friday 27 September 2024.Powered by Capital Market - Live
The said drug is therapeutically equivalent to the reference listed drug product (RLD), Invega extended-release tablets of Janssen Pharmaceuticals, Inc. Paliperidone extended-release tablets are used to treat the symptoms of psychotic disorders, including schizophrenia. it is also indicated for the treatment of schizoaffective disorder, both as a monotherapy and as an adjunct to mood stabilizers and antidepressants. Paliperidone extended-release tablets, have an estimated market size of $ 48 million for twelve months ending June 2024, according to IQVIA. Alembic has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip shed 0.29% to Rs 1,192.45 on the BSE.Powered by Capital Market - Live
Alembic Pharmaceuticals has appointed Sudhakar Pandiyan as Head - Technical Operations (Sterile & Oncology), designated as Senior Management Personnel of the Company w.e.f. 16 September 2024. Powered by Capital Market - Live
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Albendazole Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), LAlbenza Tablets, 200 mg, of Impax Laboratories, Inc. (Impax). Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. It is also indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip slipped 1.50% to settle at Rs 1,100.55 on Friday, 23 August 2024. Powered by Capital Market - Live
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Refer label for a detailed indication. Alembic has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.67%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.8% to 1.66%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 1.05%, vs industry avg of 15.28%